Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

Cordis appointments: Johnson & Johnson interventional cardiology division has filled three VP-level positions, the firm said Oct. 13. Carl St. Bernard joins Cordis as VP of U.S. sales and marketing. He was previously general manager of the magnetic resonance imaging unit at GE Healthcare. Paul Chang has moved from J&J's pharmaceutical R&D team to become Cordis' VP-worldwide clinical research and operations. Finally, Ryan Saadi, formerly of Genzyme, is tapped to fill the health economics and reimbursement VP role. A Cordis spokesperson would not comment on progress in filling two other high-level positions for worldwide president and chief medical officer previously reported to be vacant (1"The Gray Sheet" June 23, 2008, p. 8)
Advertisement

Related Content

People In Brief
People In Brief
Endocare To Shed Non-Core Assets, Focus On Cryocare Indications
Advertisement
UsernamePublicRestriction

Register

MT026700

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel